Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Angew Chem Int Ed Engl ; 60(2): 716-720, 2021 01 11.
Artículo en Inglés | MEDLINE | ID: mdl-32936507

RESUMEN

Visualizing the functional interactions of biomolecules such as proteins and nucleic acids is key to understanding cellular life on the molecular scale. Spatial proximity is often used as a proxy for the direct interaction of biomolecules. However, current techniques to visualize spatial proximity are either limited by spatial resolution, dynamic range, or lack of single-molecule sensitivity. Here, we introduce Proximity-PAINT (pPAINT), a variation of the super-resolution microscopy technique DNA-PAINT. pPAINT uses a split-docking-site configuration to detect spatial proximity with high sensitivity, low false-positive rates, and tunable detection distances. We benchmark and optimize pPAINT using designer DNA nanostructures and demonstrate its cellular applicability by visualizing the spatial proximity of alpha- and beta-tubulin in microtubules using super-resolution detection.


Asunto(s)
Microscopía Fluorescente/métodos , Tubulina (Proteína)/análisis , Anticuerpos/inmunología , ADN/química , ADN/metabolismo , Transferencia Resonante de Energía de Fluorescencia , Microtúbulos/química , Nanoestructuras/química , Hibridación de Ácido Nucleico , Tubulina (Proteína)/inmunología
2.
Behav Brain Sci ; 42: e154, 2019 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-31506137

RESUMEN

Joshua May responds to skepticism about moral knowledge via appeal to empirical work on moral foundations. I demonstrate that the moral foundations literature is not able to do the work May needs. It demonstrates shared moral cognition, not shared moral judgment, and therefore, May's attempt to defeat general skepticism fails.

3.
J Can Dent Assoc ; 83: h7, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-29513209

RESUMEN

Temporomandibular disorder (TMD) is a collective term that includes disorders of the temporomandibular joint (TMJ) and of the masticatory muscles and their associated structures. TMDs are characterized by pain, joint sounds and restricted mandibular movement, and drugs are widely used in the management of that pain. Pharmacological agents commonly used for the treatment of TMDs include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, muscle relaxants, antidepressants, anticonvulsants and benzodiazepines. In this paper, we discuss these agents and the potential adverse drug reactions and interactions associated with their use. Temporomandibular disorder (TMD) is a collective term used for a number of clinical problems that involve the masticatory muscle complex, the temporomandibular joint (TMJ) and associated structures. TMD is one of the most common disorders in the maxillofacial region. Signs and symptoms of TMD may include pain, impaired jaw function, malocclusion, deviation from the midline on opening or closing the jaw, limited range of motion, joint noises and locking.1 Among other signs and symptoms, headaches and sleep disturbances can appear concomitantly.2 This disorder is most prevalent in people aged 20-40 years.3 Approximately 33% of the population have at least 1 TMD symptom, and 3.6-7.0% of the population have TMD with sufficient severity to seek treatment.3 There is some evidence to suggest that anxiety, stress and other emotional disturbances exacerbate TMD.4 As many as 75% of patients with TMD have a significant psychological abnormality.5 Most TMD symptoms resolve over time, but, for a significant number of patients, this may take a year or more.3 Treatment is directed toward reducing pain and improving function. Many non-invasive therapies, such as self-care, physical therapy and appliance therapy, are commonly used for the treatment of TMD.3 Pharmacological intervention has been used for many years, and the most effective pharmacological agents for the treatment of TMD include analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, anxiolytics, muscle relaxants, antidepressants, anticonvulsants and benzodiazepines. However, we found only 1 relevant Cochrane study, which included 11 randomized controlled trials of pharmacotherapy for TMD.6 In this article, we review the pharmacology and research supporting the use of a host of pharmacologic agents that have been prescribed for patients who have TMD. The decision to select any of these agents depends on a full understanding of the drug's risks and benefits.


Asunto(s)
Trastornos de la Articulación Temporomandibular/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Analgésicos Opioides/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Anticonvulsivantes/uso terapéutico , Antidepresivos/uso terapéutico , Benzodiazepinas/uso terapéutico , Interacciones Farmacológicas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Relajantes Musculares Centrales/uso terapéutico
4.
J Can Dent Assoc ; 82: h2, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-28240575

RESUMEN

Objective: To investigate Ontario dentists' perceptions of patient interest in sedation and general anesthesia (GA) during treatment and patient fear and avoidance of dental treatment. Methods: Using the Royal College of Dental Surgeons of Ontario roster, we randomly selected 3001 practising Ontario dentists, from among those who listed an email address, to complete a 16-question survey by mail or online. Demographic information (e.g., gender, size and type of primary practice, and years of experience) was collected as well as dentist reports of patient interest in sedation/GA and level of fear regarding treatment. Analysis included sample t-tests to compare Ontario dentist responses with patient responses to a 2002 national survey. Results: 1076 dentists participated (37.9% response rate), comprised of 69.7% males, 84.4% general practitioners, 0.5­42 years of practice (mean 20.6 years), and 40.6% from cities with a population larger than 500,000. Dentists underestimated patients' interest in sedation/GA, with dentists and patients reporting patients "Not interested" as 66.8% and 43.9%, respectively, and "Interested depending on cost," 19.8% v. 42.3%. Dentists also underestimated patient interest in sedation/GA for specific dental procedures including scaling, fillings/crowns, root canal therapy and periodontal surgery (p < 0.01). Dentists overestimated patient fear levels ("Somewhat afraid," 19.9% v. 9.8%; "Very afraid," 10.6% v. 2.0%; "Terrified," 6.0% v. 3.5%) and the proportion of patients avoiding dental care (13.3% v. 7.6%). Conclusion: Dentists underestimate patients' preference for sedation/GA and overestimate their fear and avoidance of dental care. The significant disparities between the views of dentists and patients may affect the availability and provision of sedation and general anesthesia in Ontario dental practices.


Asunto(s)
Anestesia Dental/psicología , Actitud del Personal de Salud , Ansiedad al Tratamiento Odontológico/psicología , Cooperación del Paciente/psicología , Prioridad del Paciente/psicología , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ontario , Encuestas y Cuestionarios
5.
J Can Dent Assoc ; 80: f18, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26679331

RESUMEN

Current demographic data clearly show that the North American population is aging, and projections suggest that the percentage of older people will increase. The elderly often suffer from multiple chronic conditions that affect their quality of life, use of health services, morbidity and mortality. Also, in those of advanced age, the pharmacokinetics and pharmacodynamics of many drugs are altered. Polypharmacy increases the incidence of adverse drug reactions and drug interactions in this population. Thus, the dentist must be continually aware of the pharmacologic status of each patient and consider the likelihood of interactions between drugs prescribed by the dentist, drugs prescribed by the physician and drugs that are self-administered, including over-the-counter medications and natural supplements. In this article, we discuss pharmacokinetic and pharmacodynamic changes in the elderly patient, polypharmacy and the changes in prescribing for our dental patients. Specific emphasis is placed on the drugs commonly prescribed by dentists: local anesthetics, analgesics and antibiotics.


Asunto(s)
Analgésicos/farmacología , Anestésicos Locales/farmacología , Antibacterianos/farmacología , Cuidado Dental para Ancianos , Pautas de la Práctica en Odontología/estadística & datos numéricos , Factores de Edad , Anciano , Analgésicos/farmacocinética , Anestésicos Locales/farmacocinética , Antibacterianos/farmacocinética , Enfermedad Crónica , Comorbilidad , Interacciones Farmacológicas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , América del Norte , Polifarmacia
6.
Anesth Prog ; 62(4): 140-52, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26650492

RESUMEN

The objective of this study was to determine the prevalence, severity, and duration of postoperative pain in children undergoing general anesthesia for dentistry. This prospective cross-sectional study included 33 American Society of Anesthesiology (ASA) Class I and II children 4-6 years old requiring multiple dental procedures, including at least 1 extraction, and/or pulpectomy, and/or pulpotomy of the primary dentition. Exclusion criteria were children who were developmentally delayed, cognitively impaired, born prematurely, taking psychotropic medications, or recorded baseline pain or analgesic use. The primary outcome of pain was measured by parents using the validated Faces Pain Scale-Revised (FPS-R) and Parents' Postoperative Pain Measure (PPPM) during the first 72 hours at home. The results showed that moderate-to-severe postoperative pain, defined as FPS-R ≥ 6, was reported in 48.5% of children. The prevalence of moderate-to-severe pain was 29.0% by FPS-R and 40.0% by PPPM at 2 hours after discharge. Pain subsided over 3 days. Postoperative pain scores increased significantly from baseline (P < .001, Wilcoxon matched pairs signed rank test). Moderately good correlation between the 2 pain measures existed 2 and 12 hours from discharge (Spearman rhos correlation coefficients of 0.604 and 0.603, P < .005). In conclusion, children do experience moderate-to-severe pain postoperatively. Although parents successfully used pain scales, they infrequently administered analgesics.


Asunto(s)
Anestesia Dental/métodos , Anestesia General/métodos , Dolor Postoperatorio/etiología , Periodo de Recuperación de la Anestesia , Antiinflamatorios no Esteroideos/uso terapéutico , Niño , Conducta Infantil , Preescolar , Estudios Transversales , Femenino , Humanos , Ibuprofeno/uso terapéutico , Masculino , Dimensión del Dolor/métodos , Relaciones Padres-Hijo , Estudios Prospectivos , Pulpectomía/métodos , Pulpotomía/métodos , Factores de Tiempo , Extracción Dental/métodos , Diente Primario/cirugía
7.
Anesth Prog ; 58(2): 82-92, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21679044

RESUMEN

The risk for complications while providing any level of sedation or general anesthesia is greatest when caring for patients having significant medical compromise. It is reassuring that significant untoward events can generally be prevented by careful preoperative assessment, along with attentive intraoperative monitoring and support. Nevertheless, we must be prepared to manage untoward events should they arise. This continuing education article will review respiratory considerations and will be followed by a subsequent article addressing cardiovascular considerations.


Asunto(s)
Manejo de la Vía Aérea/métodos , Sedación Consciente/efectos adversos , Sedación Profunda/efectos adversos , Tratamiento de Urgencia/métodos , Oxígeno/administración & dosificación , Insuficiencia Respiratoria/terapia , Manejo de la Vía Aérea/instrumentación , Obstrucción de las Vías Aéreas/terapia , Cartílago Cricoides/cirugía , Humanos , Intubación Intratraqueal/instrumentación , Máscaras Laríngeas , Respiración con Presión Positiva/instrumentación , Náusea y Vómito Posoperatorios/terapia , Insuficiencia Respiratoria/etiología , Traqueotomía
8.
Anesth Prog ; 58(3): 126-38, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21882989

RESUMEN

The risk for cardiovascular complications while providing any level of sedation or general anesthesia is greatest when caring for patients already medically compromised. It is reassuring that significant untoward events can generally be prevented by careful preoperative assessment, along with attentive intraoperative monitoring and support. Nevertheless, providers must be prepared to manage untoward events should they arise. This continuing education article will review cardiovascular complications and address their appropriate management.


Asunto(s)
Enfermedades Cardiovasculares/etiología , Sedación Consciente/efectos adversos , Sedación Profunda/efectos adversos , Angina de Pecho/etiología , Arritmias Cardíacas/etiología , Reanimación Cardiopulmonar , Enfermedades Cardiovasculares/tratamiento farmacológico , Tratamiento de Urgencia , Humanos , Hipertensión/etiología , Hipotensión/etiología , Infarto del Miocardio/etiología , Síncope Vasovagal/etiología
9.
Elife ; 92020 09 17.
Artículo en Inglés | MEDLINE | ID: mdl-32940605

RESUMEN

JCPyV polyomavirus, a member of the human virome, causes progressive multifocal leukoencephalopathy (PML), an oft-fatal demyelinating brain disease in individuals receiving immunomodulatory therapies. Mutations in the major viral capsid protein, VP1, are common in JCPyV from PML patients (JCPyV-PML) but whether they confer neurovirulence or escape from virus-neutralizing antibody (nAb) in vivo is unknown. A mouse polyomavirus (MuPyV) with a sequence-equivalent JCPyV-PML VP1 mutation replicated poorly in the kidney, a major reservoir for JCPyV persistence, but retained the CNS infectivity, cell tropism, and neuropathology of the parental virus. This mutation rendered MuPyV resistant to a monoclonal Ab (mAb), whose specificity overlapped the endogenous anti-VP1 response. Using cryo-EM and a custom sub-particle refinement approach, we resolved an MuPyV:Fab complex map to 3.2 Å resolution. The structure revealed the mechanism of mAb evasion. Our findings demonstrate convergence between nAb evasion and CNS neurovirulence in vivo by a frequent JCPyV-PML VP1 mutation.


Asunto(s)
Anticuerpos Monoclonales/inmunología , Cápside/inmunología , Mutación , Poliomavirus/patogenicidad , Animales , Femenino , Leucoencefalopatía Multifocal Progresiva/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Poliomavirus/inmunología , Virulencia
10.
J Can Dent Assoc ; 75(8): 579, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19840499

RESUMEN

OBJECTIVE: Paresthesia is an adverse event that may be associated with the administration of local anesthetics in dentistry. The purpose of this retrospective study was to analyze cases of paresthesia associated with local anesthetic injection that were voluntarily reported to Ontario"s Professional Liability Program (PLP) from 1999 to 2008 inclusive, to see if the findings were consistent with those from 1973 to 1998 from this same source. MATERIALS AND METHODS: All cases of nonsurgical paresthesia reported from 1999 to 2008 were reviewed; cases involving surgical procedures were excluded. Variables examined included patient age and gender, type and volume of local anesthetic, anatomic site of nerve injury, affected side and pain on injection or any other symptoms. RESULTS: During the study period, 182 PLP reports of paresthesia following nonsurgical procedures were made; all but 2 were associated with mandibular block injection. There was no significant gender predilection, but the lingual nerve was affected more than twice as frequently as the inferior alveolar nerve. During 2006-2008 alone, 64 cases of nonsurgical paresthesia were reported to PLP, a reported incidence of 1 in 609,000 injections. For the 2 local anesthetic drugs available in dental cartridges as 4% solutions, i.e., articaine and prilocaine, the frequencies of reporting of paresthesia were significantly greater than expected (chi2, exact binomial distribution; p < 0.01) based on their level of use by Ontario dentists. These data suggest that local anesthetic neurotoxicity may be at least partly involved in the development of postinjection paresthesia.


Asunto(s)
Anestesia Dental/efectos adversos , Anestésicos Locales/efectos adversos , Parestesia/epidemiología , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Anestesia Dental/estadística & datos numéricos , Anestésicos Locales/administración & dosificación , Canadá/epidemiología , Carticaína/efectos adversos , Niño , Mentón/inervación , Femenino , Humanos , Inyecciones/efectos adversos , Inyecciones/estadística & datos numéricos , Traumatismos del Nervio Lingual , Enfermedades de los Labios/epidemiología , Masculino , Persona de Mediana Edad , Bloqueo Nervioso/efectos adversos , Bloqueo Nervioso/estadística & datos numéricos , Prilocaína/efectos adversos , Estudios Retrospectivos , Factores Sexuales , Enfermedades de la Lengua/epidemiología , Traumatismos del Nervio Trigémino , Programas Voluntarios , Adulto Joven
11.
J Can Dent Assoc ; 75(9): 649, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19900354

RESUMEN

OBJECTIVE: Local anesthetics are believed to be the most frequently used drugs in clinical dentistry, and although they are generally regarded as safe, some adverse reactions can be expected and do occur. The purpose of this study was to obtain, by means of a mail survey, information on the types and amounts of local anesthetics used by Ontario dentists during 2007. MATERIALS AND METHODS: A survey requesting data on the annual use of injectable local anesthetics was mailed to all 8,058 dentists licensed by the Royal College of Dental Surgeons of Ontario in 2007. RESULTS: The effective response rate to the single mailing was 17.3% (1,395 respondents). By extrapolation, the estimated use of local anesthetics by all Ontario dentists during 2007 was determined to be about 13 million cartridges, which represents an average of 1,613 cartridges per dentist per year. Lidocaine with epinephrine 1:100,000 was the most commonly used formulation with 37.31% of total anesthetic use, followed by articaine with 1:200,000 epinephrine (27.04%) and articaine with 1:100,000 epinephrine (17.16%). Overall, local anesthetics combined with a vasoconstrictor accounted for more than 90% of total anesthetic use. A minority of survey respondents (15.68%) indicated that their pattern of anesthetic use had changed significantly in the past few years. Patterns of use were similar for early and late survey respondents. These data provide a current account of the use of local anesthetics by Ontario dentists.


Asunto(s)
Anestesia Dental/estadística & datos numéricos , Anestésicos Locales/administración & dosificación , Pautas de la Práctica en Odontología/estadística & datos numéricos , Bupivacaína/administración & dosificación , Carticaína/administración & dosificación , Epinefrina/administración & dosificación , Humanos , Lidocaína/administración & dosificación , Mepivacaína/administración & dosificación , Ontario , Prilocaína/administración & dosificación , Vasoconstrictores/administración & dosificación
12.
Anesth Prog ; 56(2): 36-41, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19642717

RESUMEN

The objective of this study was to determine the effect of time on the clinical efficacy of topical anesthetic in reducing pain from needle insertion alone as well as injection of anesthetic. This was a randomized, double-blind, placebo-controlled, split-mouth, clinical trial which enrolled 90 subjects, equally divided into 3 groups based upon time (2, 5, or 10 minutes) of topical anesthetic (5% lidocaine) application. Each group was further subdivided into 2: needle insertion only in the palate or needle insertion with deposition of anesthetic (0.5 mL 3% mepivacaine plain). Each subject received drug on one side and placebo on the other. Subjects recorded pain on a 100-mm visual analog scale (VAS). The results showed that for needle insertion only, 5% lidocaine reduced pain as determined by a significant difference in mean VAS after 2 minutes (20.1 mm, P < .002), 5 minutes (15.7 mm, P < .022), and 10 minutes (13.7 mm, P < .04), as analyzed by paired t tests. For needle insertion plus injection of local anesthetic, a significant difference in mean VAS was noted only after 10 minutes (14.9 mm, P < .031), yet pain scores for both topical anesthetic and placebo were elevated at this time point resulting in no reduction in actual pain. Time of application did not result in a significant difference in effect for either needle insertion only or needle insertion plus injection of local anesthetic, as analyzed by 1-way analysis of variance (ANOVA). In conclusion, topical anesthetic reduces pain of needle insertion if left on palatal mucosa for 2, 5, or 10 minutes, but has no clinical pain relief for anesthetic injection.


Asunto(s)
Anestesia Dental/métodos , Anestesia Local , Anestésicos Locales/administración & dosificación , Lidocaína/administración & dosificación , Administración Tópica , Adolescente , Adulto , Método Doble Ciego , Dolor Facial/etiología , Dolor Facial/prevención & control , Femenino , Humanos , Inyecciones/efectos adversos , Masculino , Persona de Mediana Edad , Agujas/efectos adversos , Dimensión del Dolor , Estudios Prospectivos , Análisis de Regresión , Factores de Tiempo , Adulto Joven
13.
Anesth Prog ; 66(3): 141-150, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31545669

RESUMEN

Our objective was to estimate the prevalence of mortality and serious morbidity for office-based deep sedation and general anesthesia (DS/GA) for dentistry in Ontario from 1996 to 2015. Data were collected retrospectively in 2 phases. Phase I involved the review of incidents, and phase II involved a survey of DS/GA providers. In phase I, cases involving serious injury or death for dentistry under DS/GA, sourced from the Office of the Chief Coroner of Ontario and from the Royal College of Dental Surgeons of Ontario (RCDSO), were reviewed. Phase II involved a survey of all RCDSO-registered providers of DS/GA in which they were asked to estimate the number of DS/GAs administered in 2015 and the number of years in practice since 1996. Clinician data were pooled to establish an overall number of DS/GAs administered in dental offices in Ontario from 1996 to 2015. Prevalence was calculated using phase I (numerator) and phase II (denominator) findings. The estimated prevalence of mortality in the 20-year period from 1996 to 2015 was 3 deaths in 3,742,068 cases, with an adjusted mortality rate of 0.8 deaths per 1 million cases. The estimated prevalence of serious morbidity was 1 injury in 3,742,068 cases, which adjusts to a serious morbidity rate of 0.25 per 1 million cases. The mortality rate found in this study was slightly lower than those published by earlier studies conducted in Ontario. The risk of serious morbidity was found to be low and similar to other studies investigating morbidity in office-based dental anesthesia.


Asunto(s)
Anestesia Dental , Anestesia General , Sedación Profunda , Anestesia Dental/efectos adversos , Anestesia Dental/mortalidad , Anestesia General/efectos adversos , Anestesia General/mortalidad , Humanos , Ontario/epidemiología , Estudios Retrospectivos
14.
Nat Commun ; 9(1): 1600, 2018 04 23.
Artículo en Inglés | MEDLINE | ID: mdl-29686288

RESUMEN

Self-assembled DNA nanostructures feature an unprecedented addressability with sub-nanometer precision and accuracy. This addressability relies on the ability to attach functional entities to single DNA strands in these structures. The efficiency of this attachment depends on two factors: incorporation of the strand of interest and accessibility of this strand for downstream modification. Here we use DNA-PAINT super-resolution microscopy to quantify both incorporation and accessibility of all individual strands in DNA origami with molecular resolution. We find that strand incorporation strongly correlates with the position in the structure, ranging from a minimum of 48% on the edges to a maximum of 95% in the center. Our method offers a direct feedback for the rational refinement of the design and assembly process of DNA nanostructures and provides a long sought-after quantitative explanation for efficiencies of DNA-based nanomachines.


Asunto(s)
ADN/química , Simulación de Dinámica Molecular , Imagen Molecular/métodos , Nanoestructuras/química , ADN/ultraestructura , Análisis de Elementos Finitos , Microscopía de Fuerza Atómica , Nanoestructuras/ultraestructura , Nanotecnología/métodos , Conformación de Ácido Nucleico , Programas Informáticos
15.
Anesth Prog ; 54(2): 59-68; quiz 69, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17579505

RESUMEN

The risk for complications while providing moderate and deep sedation is greatest when caring for patients already medically compromised. It is reassuring that significant untoward events can generally be prevented by careful preoperative assessment, along with attentive intraoperative monitoring and support. Nevertheless, we must be prepared to manage untoward events should they arise. This continuing education article will review critical aspects of patient management of respiratory and cardiovascular complications.


Asunto(s)
Anestesia General , Sedación Consciente , Cardiopatías/terapia , Enfermedades Respiratorias/terapia , Obstrucción de las Vías Aéreas/terapia , Anestesia General/efectos adversos , Angina de Pecho/terapia , Arritmia Sinusal/terapia , Presión Sanguínea/fisiología , Espasmo Bronquial/terapia , Sedación Consciente/efectos adversos , Urgencias Médicas , Paro Cardíaco/terapia , Cardiopatías/prevención & control , Humanos , Hipertensión/terapia , Hipotensión/terapia , Máscaras Laríngeas , Laringismo/terapia , Cuidados para Prolongación de la Vida , Máscaras , Infarto del Miocardio/terapia , Terapia por Inhalación de Oxígeno/instrumentación , Respiración con Presión Positiva , Trastornos Respiratorios/prevención & control , Trastornos Respiratorios/terapia , Enfermedades Respiratorias/prevención & control , Volumen Sistólico/fisiología , Taquicardia/terapia
16.
J Am Dent Assoc ; 137(4): 502-13, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16637480

RESUMEN

BACKGROUND: Concerns about the safety of pediatric oral sedation and the incremental use of triazolam in adults prompted a workshop cosponsored by several professional organizations. OVERVIEW: There is a strong need and demand for adult and pediatric sedation services. Using oral medication to achieve anxiolysis in adults appears to have a wide margin of safety. Mortality and serious morbidity, however, have been reported with oral conscious sedation, especially in young children. Most serious adverse events are related to potentially avoidable respiratory complications. CONCLUSIONS: Clinical trials are needed to evaluate oral sedative drugs and combinations, as well as to develop discharge criteria with objective quantifiable measures of home readiness. Courses devoted to airway management should be developed for dentists who provide conscious sedation services. State regulation of enteral administration of sedatives to achieve conscious sedation is needed to ensure safety. PRACTICE IMPLICATIONS: Safety in outpatient sedation is of paramount concern, with enteral administration of benzodiazepines appearing safe but poorly documented in the office setting. Conscious sedation by the enteral route, including incremental triazolam, necessitates careful patient evaluation, monitoring, documentation, facilities, equipment and personnel as described in American Dental Association and American Academy of Pediatric Dentistry guidelines.


Asunto(s)
Anestesia Dental/efectos adversos , Ansiolíticos/efectos adversos , Sedación Consciente/efectos adversos , Atención Dental para Niños/métodos , Triazolam/efectos adversos , Adulto , Anestesia Dental/métodos , Ansiolíticos/administración & dosificación , Ansiolíticos/farmacocinética , Niño , Sedación Consciente/métodos , Ansiedad al Tratamiento Odontológico/tratamiento farmacológico , Humanos , Triazolam/administración & dosificación , Triazolam/farmacocinética
17.
J Am Coll Dent ; 73(3): 5-10, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17477212

RESUMEN

Permanent paresthesia following a local anesthetic injection is a possible adverse event. Epidemiological studies have suggested that the 4% solutions used in dentistry, namely prilocaine and articaine, are more highly associated with this occurrence. This article reviews the epidemiological evidence regarding articaine and paresthesia.


Asunto(s)
Anestesia Dental/efectos adversos , Anestésicos Locales/efectos adversos , Carticaína/efectos adversos , Parestesia/inducido químicamente , Anestesia Dental/métodos , Relación Dosis-Respuesta a Droga , Traumatismos del Nervio Facial/inducido químicamente , Humanos , Soluciones , Factores de Tiempo
18.
Physiol Biochem Zool ; 78(3): 373-83, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15887084

RESUMEN

The acid-base status of extra- and intracellular fluids was studied in relation to the anaerobic energy metabolism in the adductor muscle, mantle, gills, and heart of the marine bivalve Crassostrea gigas after exposure to air for periods of 2, 4, 8, 12, 24, and 48 h. Such exposure was found to cause a significant reduction in the pH in the hemolymph (pH(e)) within the first 4 h. The decrease in the pHe was accompanied by elevated Pco2 values, causing [HCO3-] to rise (respiratory acidosis). Thereafter, the pHe fell at a lower rate, and this fall was partially compensated for by a further increase in [HCO3-] in the hemolymph. The increase in the [Ca] levels in the hemolymph indicates a mobilization of Ca2+ from CaCO3 and the involvement of bicarbonates in the buffering of pHe. The main anaerobic end-products that accumulated in the tissues during the first stages of anaerobiosis were alanine and succinate, at a ratio of about 2 : 1. Later on, propionate and acetate were also accumulated at significant rates. In contrast to the adductor muscle, gills, and mantle, opine production in the heart was significant after 12-24 h of exposure to air. Determination of intracellular pH (pHi) revealed that there is a close relationship between the rate of anaerobic end-product accumulation and the extent of intracellular acidosis in the adductor muscle, mantle, and gills. On the contrary, accumulation of anaerobic end-products in the heart did not cause any significant change in its pHi. The intracellular nonbicarbonate, nonphosphate buffering value (beta (NB,NPi)) was determined to be higher in the heart than in the other three tissues and thus probably plays a crucial role in stabilizing heart pHi during exposure to air.


Asunto(s)
Equilibrio Ácido-Base/fisiología , Aire , Metabolismo Energético/fisiología , Líquido Extracelular/química , Hemolinfa/química , Ostreidae/metabolismo , Animales , Calcio/análisis , Calcio/sangre , Dióxido de Carbono/análisis , Dióxido de Carbono/sangre , Concentración de Iones de Hidrógeno , Ostreidae/fisiología , Vísceras/metabolismo
19.
J Am Dent Assoc ; 134(7): 869-76, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12892444

RESUMEN

BACKGROUND: The authors conducted this study to compare the pain on injection of the three mandibular block techniques and to determine the effect that the delivery of nitrous oxide:oxygen, or N2O:O2, had on this pain. METHODS: Based on sample size calculation, the authors randomly assigned 60 subjects to receive either local anesthetic alone or local anesthetic with N2O:O2 titrated to effect. Each subject received two mandibular block injections bilaterally from three possible pairings: Gow-Gates/standard block, standard block/Vazirani-Akinosi or Gow-Gates/ Vazirani-Akinosi. Subjects scored their pain using a 100-millimeter visual analog scale immediately after each injection. The authors analyzed data using analysis of variance, Student t tests and multiple regression analyses. RESULTS: There were no significant differences in pain on injection among the three injection techniques. The subjects in the group that received N2O:O2 and the local anesthetic demonstrated a statistically significant reduction in pain on injection compared with subjects in the group that received the local anesthetic only (P < .05). When N2O:O2 was used, there was a statistically significant decrease in pain with the first injection (P < .0005), an effect not seen with the second injection. CONCLUSIONS: There was no significant difference in pain among the three mandibular block techniques. N2O:O2 can reduce pain on the first injection given, but this effect is not seen subsequently. CLINICAL IMPLICATIONS: The decision to select one of the three mandibular block techniques should be based on factors other than pain on injection. N2O:O2 reduces pain on the first injection only.


Asunto(s)
Anestesia Dental/efectos adversos , Anestésicos por Inhalación/administración & dosificación , Nervio Mandibular , Bloqueo Nervioso/efectos adversos , Óxido Nitroso/administración & dosificación , Oxígeno/administración & dosificación , Adolescente , Adulto , Análisis de Varianza , Anestesia Dental/métodos , Anestésicos Locales/administración & dosificación , Estudios Cruzados , Femenino , Humanos , Inyecciones/efectos adversos , Lidocaína/administración & dosificación , Modelos Lineales , Masculino , Persona de Mediana Edad , Bloqueo Nervioso/métodos , Dolor/etiología , Dimensión del Dolor , Tamaño de la Muestra
20.
Dent Clin North Am ; 46(4): 815-30, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12442734

RESUMEN

There is universal agreement that dentists require emergency drugs to be readily available. Opinions differ as to the specific drugs that should comprise an emergency kit. This article has provided one opinion. Oxygen, epinephrine, nitroglycerin, injectable diphenhydramine or chlorpheniramine, albuterol, and aspirin should be readily available in a dental office. Other drugs such as glucagon, atropine, ephedrine, hydrocortisone, morphine or nitrous oxide, naloxone, midazolam or lorazepam, and flumazenil should also be considered. There are differences in the level of training of dentists in the management of medical emergencies [25]. Therefore the final decision should be made by the individual dentist who is in the best position to determine the appropriateness of these agents for the particular practice. Despite the best efforts at prevention, emergencies may still arise. Plans to manage these events are needed and there is the possibility that the drugs discussed above may be required. Their presence may save a life.


Asunto(s)
Atención Odontológica , Quimioterapia , Tratamiento de Urgencia , Agonistas Adrenérgicos/uso terapéutico , Adulto , Analgésicos Opioides/uso terapéutico , Antialérgicos/uso terapéutico , Antiinflamatorios/uso terapéutico , Broncodilatadores/uso terapéutico , Niño , Urgencias Médicas , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Humanos , Hipnóticos y Sedantes/uso terapéutico , Hipoglucemiantes/uso terapéutico , Antagonistas de Narcóticos/uso terapéutico , Terapia por Inhalación de Oxígeno , Parasimpatolíticos/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Esteroides , Vasodilatadores/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA